FinscoFinsco

ClearPoint Neuro (US.CLPT)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CLPT · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion105.7%→
ROE-193.8%↓
Cash Conversion-→
D/E Ratio5.93↓
Gross Margin62.9%→
US.CLPT (ClearPoint Neuro) | YoY: 2026 H1 vs 2025 H1


Metric             Value  YoY
-----------------------------
FCF Conversion    105.7%    →
ROE              -193.8%    ↓
Cash Conversion        -    →
D/E Ratio           5.93    ↓
Gross Margin       62.9%    →
Key Metrics
US.CLPT (ClearPoint Neuro) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
-----------------------------
FCF Conversion 105.7% →
ROE -193.8% ↓
Cash Conversion - →
D/E Ratio 5.93 ↓
Gross Margin 62.9% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies